Treatment completion and toxicity of trastuzumab or trastuzumab + lapatinib in older patients (pts): BIG 2-06; NCCTG N063D (Alliance).

Noam Pondé,Dominique Agbor-Tarh,Lissandra Dal Lago,Larissa A. Korde,Florentine Hilbers,Christian Jackisch,Olena Werner,Richard D. Gelber,Aminah Jatoi,Amylou C. Dueck,Alvaro Moreno Aspitia,Christos Sotiriou,Evandro de Azambuja,Martine Piccart

Treatment completion and toxicity of trastuzumab or trastuzumab + lapatinib in older patients (pts): BIG 2-06; NCCTG N063D (Alliance).

2019

Noam Pondé
Dominique Agbor-Tarh
Lissandra Dal Lago
Larissa A. Korde
Florentine Hilbers
Christian Jackisch
Olena Werner
Richard D. Gelber
Aminah Jatoi
Amylou C. Dueck
Alvaro Moreno Aspitia
Christos Sotiriou
Evandro de Azambuja
Martine Piccart

11553Background: Little is known about the toxicity of trastuzumab (T) or of trastuzumab + lapatinib (T + L), approved in the advanced setting, in older pts. We have performed a sub-analysis of the...

Keywords:

Toxicity
Internal medicine
Oncology
Treatment completion
Trastuzumab
Medicine
Lapatinib
Physical therapy
older patients

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations